The stock of PTC Therapeutics Inc (PTCT) has gone down by -9.89% for the week, with a -18.86% drop in the past month and a -9.66% drop in the past quarter. The volatility ratio for the week is 4.72%, and the volatility levels for the past 30 days are 4.77% for PTCT.. The simple moving average for the past 20 days is -11.23% for PTCT’s stock, with a -15.51% simple moving average for the past 200 days.
Is It Worth Investing in PTC Therapeutics Inc (NASDAQ: PTCT) Right Now?
Additionally, the 36-month beta value for PTCT is 0.70. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 5 rating it as “hold,” and 1 rating it as “sell.”
The public float for PTCT is 73.71M and currently, short sellers hold a 13.92% ratio of that float. The average trading volume of PTCT on April 19, 2024 was 914.92K shares.
PTCT) stock’s latest price update
PTC Therapeutics Inc (NASDAQ: PTCT)’s stock price has dropped by -1.87 in relation to previous closing price of 25.16. Nevertheless, the company has seen a loss of -9.89% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-20 that PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.
Analysts’ Opinion of PTCT
Many brokerage firms have already submitted their reports for PTCT stocks, with Morgan Stanley repeating the rating for PTCT by listing it as a “Underweight.” The predicted price for PTCT in the upcoming period, according to Morgan Stanley is $28 based on the research report published on December 19, 2023 of the previous year 2023.
Wells Fargo, on the other hand, stated in their research note that they expect to see PTCT reach a price target of $37. The rating they have provided for PTCT stocks is “Overweight” according to the report published on December 08th, 2023.
Oppenheimer gave a rating of “Outperform” to PTCT, setting the target price at $165 in the report published on October 30th of the previous year.
PTCT Trading at -11.92% from the 50-Day Moving Average
After a stumble in the market that brought PTCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.74% of loss for the given period.
Volatility was left at 4.77%, however, over the last 30 days, the volatility rate increased by 4.72%, as shares sank -16.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.84% lower at present.
During the last 5 trading sessions, PTCT fell by -9.89%, which changed the moving average for the period of 200-days by -40.38% in comparison to the 20-day moving average, which settled at $27.57. In addition, PTC Therapeutics Inc saw -10.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTCT starting from Golden Lee Scott, who sale 526 shares at the price of $28.37 back on Apr 02 ’24. After this action, Golden Lee Scott now owns 59,988 shares of PTC Therapeutics Inc, valued at $14,923 using the latest closing price.
Boulding Mark Elliott, the EXEC. VP AND CLO of PTC Therapeutics Inc, sale 794 shares at $27.25 during a trade that took place back on Jan 30 ’24, which means that Boulding Mark Elliott is holding 71,189 shares at $21,637 based on the most recent closing price.
Stock Fundamentals for PTCT
Current profitability levels for the company are sitting at:
- -0.47 for the present operating margin
- 0.85 for the gross margin
The net margin for PTC Therapeutics Inc stands at -0.67. The total capital return value is set at -0.34.
Based on PTC Therapeutics Inc (PTCT), the company’s capital structure generated -0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.53. The debt to equity ratio resting at -0.37. The interest coverage ratio of the stock is -6.04.
Currently, EBITDA for the company is -112.81 million with net debt to EBITDA at 1.06. When we switch over and look at the enterprise to sales, we see a ratio of 1.83. The receivables turnover for the company is 5.82for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.02.
Conclusion
In conclusion, PTC Therapeutics Inc (PTCT) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
